CCL20 and psoriasis: Furthermore, key markers of the psoriasis disease pathology were significantly reduced in the two active arms (20 mg/30 mg) reaching a percent improvement of 52% versus 51% (IL‐17A), 41% versus 54% (CCL20) and 66% versus 60% (TNFα) at Week 16, as seen in Figure 2B.